Abstract
According to American Cancer Society statistics, 16,470 new cases and 14,530 deaths due to esophageal cancer were expected in 2009. Current estimates of 5-year overall survival in a SEER cohort were approximately 37 % for localized disease and only 17 % for all stages combined [1]. These statistics reflect a number of contributing factors. First, patients typically present with a history of progressive dysphagia and weight loss often spanning weeks to months, and with such symptoms of locally advanced disease, it is not surprising that most patients present with stage III or IV disease [historically at MD Anderson Cancer Center, fewer than 1 % of patients presented with in situ disease, and only one in five presented with local disease (Table 17.1)]. Second, the esophagus lacks a limiting serosal layer that would otherwise tend to restrict the local extension of tumor. Third, the esophagus possesses a rich network of lymphatics spanning its entire length, thereby facilitating longitudinal spread anywhere between the neck and the abdomen. As a result, regional lymph node involvement is found in more than 75 % of patients at the time of presentation. Finally, esophageal cancer is associated with a high incidence of both early invasion to adjacent structures (e.g., cardia of the stomach, pericardium, pleura, trachea, and aorta) and distant metastasis (most commonly to the lungs, liver, and bone).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Altekruse SF, Kosary CL, Krapcho M, et al., editors. SEER cancer statistics review, 1975–2007. National Cancer Institute. http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission. Updated 2010. Accessed 23 May 2012.
Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23):2241–52.
Hsu PK, Wu YC, Chou TY, et al. Comparison of the 6th and 7th editions of the American Joint Committee on Cancer tumor-node-metastasis staging system in patients with resected esophageal carcinoma. Ann Thorac Surg. 2010;89(4):1024–31.
Giuli R, Gignoux M. Treatment of carcinoma of the esophagus: retrospective study of 2,400 patients. Ann Surg. 1980;192:44–52.
Birkmeyer JD, Siewers AE, Finlayson E, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128–37.
Martin LW, Swisher SG, Hofstetter W, et al. Intrathoracic leaks following esophagectomy are no longer associated with increased mortality. Ann Surg. 2005;242:392–402.
Hofstetter W, Swisher SG, Correa AM, et al. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002;236:376–85.
Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long term followup of a prostpective randomized trial (RTOG 85-01). JAMA. 1999;281(17):1623–7.
Swisher SG, Hofstetter W, Komaki R, et al. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg. 2010;90(3):892–8 [discussion 898–9].
Lee HK, Vaporciyan AA, Cox JD, et al. Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys. 2003;57(5):1317–22.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ho, L., Hofstetter, W., Komaki, R., Lin, S.H. (2013). Esophageal Cancer. In: Rodriguez, M., Walters, R., Burke, T. (eds) 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5197-6_17
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5197-6_17
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5196-9
Online ISBN: 978-1-4614-5197-6
eBook Packages: MedicineMedicine (R0)